|
|
Effect of endocrine changes on bone metabolism and bone mineral density in patients with polycystic ovary syndrome |
HAN Zhe1 CUI Zhaohui1 LI Xinning1 LI Jiena2 ZHENG Zhixin3▲ |
1. Department of Orthopaedic Surgery, Heze Municipal Hospital, Shandong Province, Heze 274000, China;
2. Department of Obstetrics and Gynecology, Heze Municipal Hospital, Shandong Province, Heze 274000, China;
3. Department of Spine Surgery, Heze Municipal Hospital, Shandong Province, Heze 274000, China |
|
|
Abstract Objective To investigate the effect of endocrine hormonal changes on bone metabolism and bone mineral density in polycystic ovary syndrome (PCOS). Methods A total of 129 patients admitted to the Department of Gynecology and Obstetrics of Heze Municipal Hospital from January 2020 to September 2021 were selected as the research objects, 71 patients with PCOS were included in the PCOS group, and the remaining 58 premenopausal patients were included in the non PCOS group. The levels of serum 25-hydroxy vitamin D (25-[OH]VD), osteocalcin (OC), total N-terminal propeptide of typeⅠprocollagen (TP1NP), β-C-terminal telopeptide of type-Ⅰcollagen (β-CTX), total parathyroid hormone (PTH) and bone mineral density, related sex hormone were compared between two groups. Results The levels of luteinizing hormone/follicle stimulating hormone (LH/FSH), total testosterone (TT) and homeostasis model assessment-insulin resistance (HOMA-IR) in the PCOS group were higher than those of the non-PCOS group, the differences were statistically significant (P<0.05). The levels of 25-(OH)VD, OC, β-CTX, TP1NP, total T value in the PCOS group were lower than those of the non-PCOS group, the differences were statistically significant (P<0.05). There were no significant differences in the levels of estradiol, PTH and plasma fasting insulin (FINS) between the two groups (P>0.05). Conclusion Endocrine changes in PCOS patients cause bone metabolism changes and bone mineral density decline, which provide important clinical data for preventing and delaying the occurrence of osteoporosis.
|
|
|
|
|
[1] |
Di Bari F,Catalano A,Bellone F,et al.Vitamin D,Bone Meta-bolism,and Fracture Risk in Polycystic ovary Syndrome[J].Metabolites,2021,11(2):116.
|
[2] |
Krishnan A,Muthusami S.Hormonal alterations in PCOS and its influence on bone metabolism[J].J Endocrinol,2017,232(2):99-113.
|
[3] |
Vasikaran S,Cooper C,Eastell R,et al.International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis[J].Clin Chem Lab Med,2011,49(8):1271-1274.
|
[4] |
宋颖,李蓉.多囊卵巢综合征中国诊疗指南解读[J].实用妇产科杂志,2018,34(10):737-741.
|
[5] |
冯兰青,邓美香,李小景,等.PCOS患者抗苗勒管激素水平与胰岛素抵抗及生殖激素水平的相关性研究[J].生殖医学杂志,2021,30(1):30-34.
|
[6] |
景嵘月,徐蕾,徐长松,等.FRAX评估类风湿关节炎患者骨折风险及相关临床危险因素的研究[J].中国骨质疏松杂志,2021,27(9):1262-1268.
|
[7] |
程晓光,徐文坚,吴艳,等.骨质疏松的影像学与骨密度诊断专家共识[J].中国骨质疏松杂志,2020,26(9):1249-1256.
|
[8] |
Kazemi M,Jarrett B,Parry SA,et al.Osteosarcopenia in Reproductive-Aged Women with Polycystic Ovary Syndrome:A Multicenter Case-Control Study[J].J Clin Endocrinol Metab,2020,105(9):e3400-3414.
|
[9] |
Lingaiah S,Morin-Papunen L,Piltonen T,et al.Bone markers in polycystic ovary syndrome:A multicentre study[J].Clin Endocrinol (Oxf),2017,87(6):673-679.
|
[10] |
霍丽静,于芳,马倩,等.多囊卵巢综合征患者血清骨代谢标志物水平的变化研究[J].标记免疫分析与临床,2020, 27(4):591-594.
|
[11] |
Li J,Chen X,Lu L,et al.The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis[J].Cytokine Growth Factor Rev,2020,52:88-98.
|
[12] |
熊茂程,黄芮,毕冬明,等.骨代谢标志物对PCOS伴胰岛素抵抗的诊疗价值研究[J].中国疗养医学,2021,30(10):1029-1032.
|
[13] |
程晓光,袁慧书,程敬亮,等.骨质疏松的影像学与骨密度诊断专家共识[J].中国骨与关节杂志,2020,9(9):666-673.
|
[14] |
Bhattoa HP,Cavalier E,Eastell R,et al.Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood[J].Clin Chim Acta,2021,515:16-20.
|
[15] |
谢冰秀,王灶明,张康婧.新诊断2型糖尿病患者骨密度与骨代谢指标相关性研究[J].中国医药科学,2020,10(7):269-271,275.
|
[16] |
Wei X,Zhang Y,Xiang X,et al.Exploring the Relationship of Bone Turnover Markers and Bone Mineral Density in Community-Dwelling Postmenopausal Women[J].Dis Markers,2021,2021:1-10.
|
[17] |
Mu Y,Cheng D,Yin TL,et al.Vitamin D and Polycystic Ovary Syndrome:A Narrative Review[J].Reprod Sci,2021,28(8):2110-2117.
|
|
|
|